» Articles » PMID: 39674638

A Convenient Viral Transduction Based Method for Advanced Multi-engineering of Primary Human (CAR) T-cells

Overview
Specialty Biotechnology
Date 2024 Dec 14
PMID 39674638
Authors
Affiliations
Soon will be listed here.
Abstract

The past decades have illustrated the power of T-cell engineering in the development of new and successful cell therapies, such as chimeric antigen receptor (CAR) T-cells. Despite clinical success in hematological malignancies, it also becomes increasingly clear that additional T-cell engineering will be required to improve efficacy and safety and expand the application to solid tumors. Engineering is most often achieved by viral delivery of transgenes, however, viral vector capacity limitations make efficient and reproducible generation of multi transgene expressing T-cell therapeutics technically challenging. We here describe a convenient and efficient method for the delivery of up to three γ-retroviral CAR vectors in T-cells. We achieved this using virus vector mixtures that are simultaneously produced at high titers by double- or triple- transduced stable virus producer cells. We show that this method is superior in overall efficiency and reproducibility to conventional double or triple CAR transductions, in which separate viral batches are used. Due to its robustness, this method can facilitate the research and the development for advanced T-cell engineering towards more effective and safe therapies.

Citing Articles

"Attack!" Cellular Therapies to Attack Pathogens and Tumors.

Eiz-Vesper B, Bonig H Transfus Med Hemother. 2025; 52(1):1-4.

PMID: 39944410 PMC: 11813275. DOI: 10.1159/000543415.

References
1.
Kim J, Lee S, Li L, Park H, Park J, Lee K . High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One. 2011; 6(4):e18556. PMC: 3084703. DOI: 10.1371/journal.pone.0018556. View

2.
Chen J, Lopez-Moyado I, Seo H, Lio C, Hempleman L, Sekiya T . NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019; 567(7749):530-534. PMC: 6546093. DOI: 10.1038/s41586-019-0985-x. View

3.
Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J . A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther. 2017; 25(8):1946-1958. PMC: 5542711. DOI: 10.1016/j.ymthe.2017.04.024. View

4.
Ghani K, Wang X, de Campos-Lima P, Olszewska M, Kamen A, Riviere I . Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. Hum Gene Ther. 2009; 20(9):966-74. PMC: 2861952. DOI: 10.1089/hum.2009.001. View

5.
Brudno J, Maric I, Hartman S, Rose J, Wang M, Lam N . T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018; 36(22):2267-2280. PMC: 6067798. DOI: 10.1200/JCO.2018.77.8084. View